No More. It Ends Here.
- AHPRA / Medical Board Aust. (MBA) not allowed to create / lodge complaints. Anonymous complaints are disallowed. For more information on all these issues, go to GUVNOT.COM/1/10
I have alluded to this issue GUVNOT.COM/1/9.
To summarise again , our system of justice demands that every person should be able to face his accusers. This standard is generally only obviated where criminal organisations such as the Mafia may be involved in endangering the witness, hardly a situation relevant to medical practice in Australia.
Every accuser should be liable to be required to undergo examination / cross-examination in a court of law as would be a standard in any other legal action.
This includes AHPRA.
It should be forced to field representatives on the Board for Cross-examination in court.
anonymous
THE AHPRA POINT OF VIEW: on this issue
The proposal to prohibit AHPRA and the Medical Boards from initiating complaints, and to disallow anonymous complaints, misconstrues the nature of modern protective regulation. Regulators are not passive recipients of grievances; they are active guardians of public safety. Intelligence-led regulation requires the ability to initiate inquiries where patterns of risk emerge from data, audits, notifications from other agencies, or credible information not reducible to a single named complainant. To prohibit regulator-initiated matters would disable the system’s capacity to detect systemic risk.
The insistence that all complainants be identifiable and available for cross-examination ignores the power imbalances inherent in healthcare. Patients, families, colleagues, and junior staff may fear retaliation, stigma, or professional consequences if named. Anonymity functions as a safety valve that enables disclosure of concerns that would otherwise remain hidden.
Removing anonymous reporting would not purify the complaint stream; it would silence the most vulnerable voices and skew regulatory visibility toward those already empowered to speak.
The justice system analogy is inapt. Regulatory investigations are not criminal trials; they are protective inquiries designed to assess risk to the public. Due process applies at later stages, including notice, response, and review. Early-stage intake does not require courtroom standards of adversarial testing because its purpose is triage, not adjudication. To impose trial-level evidentiary thresholds at intake would paralyse preventive oversight and convert regulators into bystanders until harm is proven.
Allowing the regulator to act on its own ensures that concerns not framed as formal complaints — such as patterns of adverse outcomes, audit anomalies, or multi-source signals — can be addressed before harm escalates. The public interest is not served by requiring a named individual to bear the burden of initiating scrutiny where risk is systemic. Independence from complainant identity protects the community from the chilling effects of fear and retaliation.
Ultimately, prohibiting regulator-initiated matters and anonymous reporting would transform AHPRA from a protective authority into a complaints mailbox. That model has historically failed to detect emerging risks until harm is widespread. Preventive regulation requires the capacity to see patterns, act early, and accept information in forms that those at risk can safely provide.
Erasmus (the old dog) : Call It As I See It
Legalistic view:
Where regulators initiate complaints and then adjudicate their own allegations, separation-of-functions
concerns arise. Concentrating complainant, investigator, and enforcement roles within one institution risks
eroding procedural fairness and public confidence in neutrality.
Human interest view:
Being investigated without knowing who accused you — or whether the accusation originated within the
regulator itself — is experienced by many clinicians as disorienting and dehumanising. Even where no findings
are made, the process can fracture trust in institutions meant to safeguard fairness.
In a situation where there is no violence or abuse, protecting the accuser by allowing anonymous complaints only acts to enhance the disproportionate powers aligned with institutions like AHPRA. Are we really protecting someone, or using this strategy as a method of bypassing regulatory controls.
Patient view:
Patients want unsafe practice addressed, but they also expect systems to be fair. When processes feel opaque,
confidence in the integrity of outcomes weakens, even among those seeking protection.
Due process view:
The right to know the case against you and the source of allegations is a foundational element of natural
justice. Exceptions require narrow justifications and strict safeguards, not routine use.
Governance view:
Regulators that both generate and prosecute complaints risk confirmation bias. Independent intake screening
functions can reduce the perception and reality of self-reinforcing enforcement cycles.
Systems design view:
Effective triage can coexist with whistleblower protections. Designing clear criteria for anonymous intake and
regulator-initiated matters would preserve safety while restoring proportionality and transparency.
